Year in Review 2018 by LACOG Genitourinary Cancer Group: Urological Tumors
Several and important changes in the treatment of urological tumors occurred in 2018. The studies with apalutamide (SPARTAN) and enzalutamide (PROSPER) prior to the development of metastases benefited patients with castration resistant prostate cancer. Prostate radiotherapy to the metastatic prostat...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações Ltda.
2018-10-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.5935/1806-6054.20190003 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850210794342449152 |
|---|---|
| author | José Augusto Rinck Fabio A. Schutz Fernando C. Maluf Fernando Nunes Galvão Diogo A. Bastos Diogo Augusto Rodrigues da Rosa Andrey Soares |
| author_facet | José Augusto Rinck Fabio A. Schutz Fernando C. Maluf Fernando Nunes Galvão Diogo A. Bastos Diogo Augusto Rodrigues da Rosa Andrey Soares |
| author_sort | José Augusto Rinck |
| collection | DOAJ |
| description | Several and important changes in the treatment of urological tumors occurred in 2018. The studies with apalutamide (SPARTAN) and enzalutamide (PROSPER) prior to the development of metastases benefited patients with castration resistant prostate cancer. Prostate radiotherapy to the metastatic prostate cancer improves overall survival (OS) in men with new diagnosed and with low metastatic disease burden per CHARTEED criteria. In another analysis of this trial, the abiraterone improve OS even in low-risk de novo M1 castration-sensitive prostate cancer. A phase III trial (CARMENA) assessed the utility of cytoreductive nephrectomy in conjunction with TKI's and concluded that we could not offer it in intermediate and poor-risk patients of renal cell carcinoma (RCC). Combined immunotherapy with nivolumab plus ipilimumab (CHECKMATE-214) resulted in a greater objective response rate and prolonged OS in intermediate- and poor-risk patients with metastatic RCC. And in upper tract urothelial cancer, a study showed that adjuvant chemotherapy given after nephroureterectomy improves OS (POUT). |
| format | Article |
| id | doaj-art-8dc964e00a3945f4a0aea3bf0e8bca90 |
| institution | OA Journals |
| issn | 2526-8732 |
| language | English |
| publishDate | 2018-10-01 |
| publisher | Thieme Revinter Publicações Ltda. |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj-art-8dc964e00a3945f4a0aea3bf0e8bca902025-08-20T02:09:41ZengThieme Revinter Publicações Ltda.Brazilian Journal of Oncology2526-87322018-10-0114501410.5935/1806-6054.20190003Year in Review 2018 by LACOG Genitourinary Cancer Group: Urological TumorsJosé Augusto Rinck0Fabio A. Schutz1Fernando C. Maluf2Fernando Nunes Galvão3Diogo A. Bastos4Diogo Augusto Rodrigues da Rosa5Andrey Soares6A C Camargo Cancer Center, Clinical Oncology - São Paulo - São Paulo - BrazilLatin American Cooperative Oncology Group - LACOG, Genitourinary Cancer Group - São Paulo - São Paulo - BrazilLatin American Cooperative Oncology Group - LACOG, Genitourinary Cancer Group - São Paulo - São Paulo - BrazilLatin American Cooperative Oncology Group - LACOG, Genitourinary Cancer Group - São Paulo - São Paulo - BrazilLatin American Cooperative Oncology Group - LACOG, Genitourinary Cancer Group - São Paulo - São Paulo - BrazilLatin American Cooperative Oncology Group - LACOG, Genitourinary Cancer Group - São Paulo - São Paulo - BrazilLatin American Cooperative Oncology Group - LACOG, Genitourinary Cancer Group - São Paulo - São Paulo - BrazilSeveral and important changes in the treatment of urological tumors occurred in 2018. The studies with apalutamide (SPARTAN) and enzalutamide (PROSPER) prior to the development of metastases benefited patients with castration resistant prostate cancer. Prostate radiotherapy to the metastatic prostate cancer improves overall survival (OS) in men with new diagnosed and with low metastatic disease burden per CHARTEED criteria. In another analysis of this trial, the abiraterone improve OS even in low-risk de novo M1 castration-sensitive prostate cancer. A phase III trial (CARMENA) assessed the utility of cytoreductive nephrectomy in conjunction with TKI's and concluded that we could not offer it in intermediate and poor-risk patients of renal cell carcinoma (RCC). Combined immunotherapy with nivolumab plus ipilimumab (CHECKMATE-214) resulted in a greater objective response rate and prolonged OS in intermediate- and poor-risk patients with metastatic RCC. And in upper tract urothelial cancer, a study showed that adjuvant chemotherapy given after nephroureterectomy improves OS (POUT).http://www.thieme-connect.de/DOI/DOI?10.5935/1806-6054.20190003Review Literature as TopicUrologic NeoplasmsProstatic NeoplasmsUrinary Bladder NeoplasmsKidney NeoplasmsRevisão da Literatura como TópicoNeoplasias UrológicasNeoplasias ProstáticasNeoplasias da Bexiga UrinariaNeoplasias Renais |
| spellingShingle | José Augusto Rinck Fabio A. Schutz Fernando C. Maluf Fernando Nunes Galvão Diogo A. Bastos Diogo Augusto Rodrigues da Rosa Andrey Soares Year in Review 2018 by LACOG Genitourinary Cancer Group: Urological Tumors Brazilian Journal of Oncology Review Literature as Topic Urologic Neoplasms Prostatic Neoplasms Urinary Bladder Neoplasms Kidney Neoplasms Revisão da Literatura como Tópico Neoplasias Urológicas Neoplasias Prostáticas Neoplasias da Bexiga Urinaria Neoplasias Renais |
| title | Year in Review 2018 by LACOG Genitourinary Cancer Group: Urological Tumors |
| title_full | Year in Review 2018 by LACOG Genitourinary Cancer Group: Urological Tumors |
| title_fullStr | Year in Review 2018 by LACOG Genitourinary Cancer Group: Urological Tumors |
| title_full_unstemmed | Year in Review 2018 by LACOG Genitourinary Cancer Group: Urological Tumors |
| title_short | Year in Review 2018 by LACOG Genitourinary Cancer Group: Urological Tumors |
| title_sort | year in review 2018 by lacog genitourinary cancer group urological tumors |
| topic | Review Literature as Topic Urologic Neoplasms Prostatic Neoplasms Urinary Bladder Neoplasms Kidney Neoplasms Revisão da Literatura como Tópico Neoplasias Urológicas Neoplasias Prostáticas Neoplasias da Bexiga Urinaria Neoplasias Renais |
| url | http://www.thieme-connect.de/DOI/DOI?10.5935/1806-6054.20190003 |
| work_keys_str_mv | AT joseaugustorinck yearinreview2018bylacoggenitourinarycancergroupurologicaltumors AT fabioaschutz yearinreview2018bylacoggenitourinarycancergroupurologicaltumors AT fernandocmaluf yearinreview2018bylacoggenitourinarycancergroupurologicaltumors AT fernandonunesgalvao yearinreview2018bylacoggenitourinarycancergroupurologicaltumors AT diogoabastos yearinreview2018bylacoggenitourinarycancergroupurologicaltumors AT diogoaugustorodriguesdarosa yearinreview2018bylacoggenitourinarycancergroupurologicaltumors AT andreysoares yearinreview2018bylacoggenitourinarycancergroupurologicaltumors |